NF-κB Signaling Pathway

A comprehensive guide to the canonical and non-canonical NF-κB cascades, regulating immune responses, inflammation, and cellular survival.

Transcriptional programs regulated by NF-κB are essential to the development and maintenance of the immune system, skeletal system, and epithelium. In these cellular settings, NF-κB contributes heavily to the control of cell survival, differentiation, and proliferation.

Because of its central role in cellular homeostasis, aberrant activation of NF-κB has been associated with numerous severe pathologies, including cancer, autoimmune disease, neurodegenerative diseases, and cardiovascular disease. Currently, the NF-κB signaling pathway is most characterized and well understood in its role driving chronic inflammation and auto-immune disease.

1. NF-κB Signaling Pathway Map

The activation of NF-κB relies on the degradation of inhibitory IκB proteins, allowing the active transcription factor dimers to translocate into the nucleus. This process is driven by two distinct but interconnected cascades: the Canonical and Non-Canonical pathways.

2. The NF-κB Protein Family

The NF-κB family consists of highly conserved, structurally related transcription factors. All NF-κB proteins are characterized by the presence of a ~300-amino acid sequence on the N-terminus called the Rel homology domain (RHD). This domain is responsible for DNA binding, dimerization, and interaction with inhibitory IκB proteins.

Five distinct members comprise the mammalian NF-κB protein family:

• RelA (p65)
• RelB
• c-Rel
• p50 (NF-κB1)
• p52 (NF-κB2)

Dimerization Dynamics: These proteins cannot function alone. They must bind to κB sites in the nucleus as homo- or hetero-dimers (e.g., the classic p50/p65 heterodimer), which can exert either a positive or negative impact on gene transcription depending on the cellular context.

3. Canonical vs. Non-Canonical Pathways

There are two primary types of NF-κB signaling pathways. Both require activation through complex post-translational modifications of IκB inhibitors, but they are triggered by different receptors and utilize distinct kinase complexes.

1

The Canonical Pathway

Canonical pathway activation predominantly occurs rapidly through major immune and inflammatory receptors such as BCR, TCR, TLR4, IL-1R, or TNF-R. Activation of these receptors recruits the IKK complex (IKKα, IKKβ, and NEMO). IKKβ phosphorylates the inhibitory IκBα protein, marking it for rapid proteasomal degradation. This releases the p50/RelA (p65) heterodimer, allowing it to translocate to the nucleus and trigger an acute inflammatory response.

2

The Non-Canonical Pathway

The non-canonical pathway is slower and is typically involved in lymphoid organogenesis and B-cell survival. It is selectively activated by a subset of receptors, including CD40, BAFF, or lymphotoxin-β. This pathway relies on the activation of NF-κB Inducing Kinase (NIK), which activates IKKα. IKKα then phosphorylates the p100 precursor, leading to its partial processing into p52. The resulting RelB/p52 heterodimer translocates to the nucleus to regulate specific, long-term developmental genes.

4. Essential Target Antibodies & Proteins

To thoroughly investigate the mechanisms of inflammation and immune regulation, Biorbyt offers a comprehensive catalog of primary antibodies targeting the core components of the NF-κB cascade.

Target Molecule	Description / Pathway Role	Reagent Format
RelA (p65)	The primary transactivating subunit in the canonical pathway. Phosphorylation at Ser536 is a hallmark of activation.	Primary & Phospho-Specific Antibodies
p50 (NF-κB1)	Generated from the p105 precursor. Forms the classic canonical heterodimer with RelA (p65).	Primary Antibodies, Recombinant Protein
p52 (NF-κB2)	Generated from the p100 precursor by NIK/IKKα. Forms the non-canonical heterodimer with RelB.	Primary Antibodies
RelB	The primary transactivating subunit in the non-canonical pathway, essential for lymphoid development.	Primary Antibodies
IKKβ (IKK2)	The catalytic kinase subunit of the IKK complex responsible for phosphorylating IκBα.	Primary & Phospho-Specific Antibodies
IκBα	The primary inhibitor that sequesters p50/p65 in the cytoplasm. Degraded upon pathway activation.	Primary & Phospho-Specific Antibodies
TLR4	Toll-like receptor 4. Recognizes bacterial LPS to rapidly trigger canonical NF-κB signaling.	Primary Antibodies, Flow Cytometry

5. Pathway Inhibitors & Assays

Because of its central role in hyper-inflammatory states and oncology, the NF-κB pathway is heavily targeted by small molecule therapies. Discover our highly selective inhibitors and quantitative ELISA kits to validate your experimental models.

Pathway Inhibition BAY 11-7082 A widely used, irreversible inhibitor of IKKα/β phosphorylation, preventing the degradation of IκBα and blocking NF-κB activation. Pathway Inhibition Bortezomib A highly potent 26S proteasome inhibitor that prevents the degradation of IκB, heavily utilized in multiple myeloma research. Nuclear Translocation JSH-23 A selective inhibitor of NF-κB p65 nuclear translocation and transcriptional activity without affecting IκB degradation. Quantification NF-κB p65 Transcription Factor Assays Quantify the DNA-binding activity of active, nuclear p65 directly from cell lysates using highly sensitive ELISA formats.

6. Helping Your Research

Biorbyt has an extensive range of small molecules, antibodies, and proteins available as research reagents to target every tier of the NF-κB pathway. We provide the best service and a simple buying process allowing you to focus on your valuable research.

Take a look at our product pages where you will find competitive pricing, lead times, and easy delivery options. If you have any questions or need help finding a specific target, just ask us.